Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation

Full text
Messias, Katharina [1] ; Barroso, Rafael de Montier [1] ; Jorge, Rodrigo [1] ; Messias, Andre [1]
Total Authors: 4
[1] Ribeirao Preto Sch Med, Dept Ophthalmol Otolaryngol & Head & Neck Surg, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: DOCUMENTA OPHTHALMOLOGICA; v. 137, n. 2, p. 121-129, OCT 2018.
Web of Science Citations: 0

PurposeTo compare retinal function changes in eyes with proliferative diabetic retinopathy (PDR) after intravitreal ranibizumab (IVR), combined or not with conventional (ETDRS) or multispot laser panretinal (PASCAL) photocoagulation (PRP).MethodsThis study included laser-naive PDR patients that required PRP. Eyes were randomly and prospectively assigned to receive IVR or IVR combined with PASCAL or EDTRS. PRP was performed at baseline in 1 (PASCAL) or 2 (ETDRS) sessions. In eyes with macular edema, macular short pulse grid laser was associated with IVR at baseline and IVR was repeated monthly or quarterly if neovascularization was detected on angiography. Comprehensive ophthalmological evaluations, including SD-OCT, were performed at baseline and every 4weeks after treatment. Full-field electroretinography (ERG: extended ISCEV standard) was performed at baseline and at 12, 24 and 48weeks.ResultsIVR=13, PASCAL=15 and ETDRS=15 eyes finished 48-week follow-up. There was a statistically significant BCVA improvement of 0.1-0.3 logMAR in all groups, and fluorescein angiography leakage area (FLA) reduced in 56%, 73%, and 73% from baseline for ETDRS, IVR and PASCAL, respectively, up to 48weeks without significant differences between groups (p>0.05). A significant a- and b-wave amplitudes reduction was observed for dark- and light-adapted ERG for ETDRS and PASCAL, but only minor dark-adapted b-wave reduction was found for IVR, up to 48weeks. As an example, at week 48, combined response b-wave amplitude reduced in 181.531.4 mu V, 128.0 +/- 27.9 mu V and 82.4 +/- 15.2 mu V for ETDRS, PASCAL and IVR (p<0.05 each group), respectively. No significant difference was observed between ETDRS and PASCAL for any ERG parameter.Conclusions p id=Par4 IVR combined with single or multiple spot PRP causes similar retinal function impairment during 48weeks of observation, while IVR alone seems to be similarly effective controlling FLA without changing retinal function. (AU)

FAPESP's process: 12/16265-0 - Retinal Function in Different Therapies for Proliferative Diabetic Retinopathy
Grantee:Katharina Vieira Messias
Support type: Scholarships in Brazil - Post-Doctorate